Bradmer Reports Progression Free Survival Data From Previous Phase II Glioblastoma Multiforme Trials
July 27th, 2008 by allsoch
Bradmer Pharmaceuticals Inc. (TSX: BMR), a biopharmaceutical company dedicated to the development and commercialization of cancer therapies, released progression free survival (PFS) data from two previously conducted Phase II trials of Neuradiab(TM) in glioblastoma multiforme (GBM) patients. As an exploratory endpoint of the single arm Phase II trials, the data showed a mean overall PFS of 17.2 months in 19 GBM patients treated with Neuradiab. Bradmer is currently conducting a Phase III clinical trial, termed the GLASS-ART Trial, evaluating Neuradiab as an adjunct therapy to the current standard of care for GBM patients.
Posted in Uncategorized | No Comments »
A large study published in The Lancet Oncology has found that there are wide variations in cancer survival rates between and within many countries around the world. Professor Michel Coleman (Cancer Research UK Cancer Survival Group and London School of Hygiene and Tropical Medicine) and over 100 colleagues working on the CONCORD study analyzed 31 countries that provided data on cancer survival. Not only were there variations in survival rates for different cancers between countries, but there was also a disparity in survival between black and white people in the USA.
A report published on July 18 in the open-access journal PLoS Genetics describes a new approach to fighting cancer. Researchers have located a new type of ultrasensitive genes that seem to control the way cancer expresses itself (cancer-associated phenotypes). It is possible that the growth and survival or tumors and other disease-causing agents may be thwarted if drugs are developed that can target these genes.
Researchers at Rhode Island Hospital have identified two potential molecular markers that may predict outcomes for patients with stomach cancer, one of the most common and fatal cancers worldwide.
In two complementary studies, Weizmann Institute scientists have developed a new method for reconstructing a cell’s ‘family tree,’ and have applied this technique to trace the history of the development of cancer.
Black men and women have substantially lower survival than white men and women in the United States, but US has the highest survival for prostate cancer of all 31 countries included
Scientists at Georgia Tech have developed a potential new treatment against cancer that attaches magnetic nanoparticles to cancer cells, allowing them to be captured and carried out of the body. The treatment, which has been tested in the laboratory and will now be looked at in survival studies, is detailed online in the Journal of the American Chemical Society.
NEW YORK (Reuters Health) Jul 23 - Long-term survivors of brain tumors diagnosed in the first year of life have a substantial risk of neurological and cognitive complications, according to findings published in the July issue of the Archives of Disease in Childhood. These patients are also at risk of social isolation and decreased health-related quality of life.
NEW YORK (Reuters Health) Jul 23 - The presence of human T lymphotropic virus type 1 (HTLV-1) infection appears to reduce the likelihood of developing gastric cancer, possibly through a modulating effect on Helicobacter pylori activity, Japanese researchers report in the July 1st issue of the Journal of Infectious Diseases.
NEW YORK (Reuters Health) Jul 23 - High-dose immunochemotherapy can safely be administered to HIV-infected patients with adult Burkitt lymphoma, according to a report in the July 1st Cancer.